More Company News

Mereo BioPharma

FDA Fast Track Designation for Navicixizumab
07 Oct 2019Read More

Mereo BioPharma

H119 interims and corporate update
17 Sep 2019Read More

Mereo BioPharma

Setrusumab Phase IIb data to be presented at ASBMR 2019 meeting
04 Sep 2019Read More

Mereo BioPharma

Appointment of Head of Pharmaceutical Development
16 Jul 2019Read More

Mereo BioPharma

Successful Type B Meeting with U.S. FDA
15 Jul 2019Read More

Mereo BioPharma

Conversion of loan note and issue of equity
21 Jun 2019Read More

Mereo BioPharma

Update on etigilimab TIGIT partnership
13 Jun 2019Read More

Mereo BioPharma

Positive early 6-month data for BPS-804 (setrusumab) in OI
30 May 2019Read More

Mereo BioPharma

Publication of FY18 report and accounts
30 Apr 2019Read More

Mereo BioPharma

Preliminary FY18 results
29 Apr 2019Read More

1 2 3
Return to Mereo BioPharma
© 2019 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).